Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
203
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease

J. Erika HayduMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
&
Jeremy S. AbramsonMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8467-9257
ORCID Icon
Pages 2263-2264 | Received 01 Jul 2022, Accepted 02 Jul 2022, Published online: 20 Jul 2022

References

  • Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of Risk-Adapted therapy with Dose-Adjusted EPOCH-R in adults with untreated burkitt lymphoma. J Clin Oncol. 2020;38(22):2519–2529.
  • Minard-Colin V, Auperin A, Pillon M, Children’s Oncology Group, et al. Rituximab for High-Risk, mature B-Cell Non-Hodgkin's lymphoma in children. N Engl J Med. 2020;382(23):2207–2219.
  • Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859–1864.
  • Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92(6):E114–E117.
  • Seitter SJ, McClelland PH, Ahlman MA, et al. Durable remissions in two adult patients with burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center exeperience. Leuk lymphoma. 2022;:1–5.
  • Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
  • Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
  • Schuster SJ, Bishop MR, Tam CS, JULIET Investigators, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
  • Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
  • Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.